Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas

Clinical trial NCT02323880 · COMPLETED

Trial details

NCT number: NCT02323880
Sponsor: Children's Oncology Group
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Malignant Glioma Recurrent Brain Neoplasm Recurrent Childhood Central Nervous System Neoplasm Recurrent Childhood Glioblastoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Primary Central Nervous System Neoplasm WHO Grade 3 Glioma

Start date: 2015-10-30
Primary completion: 2022-09-30
Enrollment: 59

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.